<p>佛罗里达州温特帕克 --（Newsfile Corp. -2026 年 2 月 9 日）- Adia Nutrition Inc.（OTCQB: ADIA），通过其子公司 Adia Med 在再生医学领域处于领先地位，今天宣布了一项雄心勃勃的临床研究管道扩展计划，计划在 2026 年推出四到五项额外研究。这些新举措将建立在公司在使用 Adia Vita（脐带血来源的干细胞和外泌体）进行再生疗法方面的持续成功之上。</p>
<p></p>
<p><strong>自闭症研究图示</strong></p>
<p>要查看此图的增强版本，请访问：</p>
<p>https://images.newsfilecorp.com/files/10520/282995_autism_study_graphic.jpg</p>
<p>计划中的研究可能直接在佛罗里达州温特帕克的 Adia Med 诊所进行，或与美国各地的合作诊所合作进行。为了支持这一增长，Adia Med 正在与全国多家诊所积极讨论，以获得机构审查委员会（IRB）的批准，并实现多地点参与。</p>
<p>目前正在讨论的优先工作包括：</p>
<ul>
<li>扩大当前获得 IRB 批准的自闭症谱系障碍（ASD）研究（ClinicalTrials.gov NCT07304440），将研究对象扩展到 13 岁的儿童，超出现有的 3-12 岁年龄范围，使更多家庭能够获得结合 Adia Vita 与谷胱甘肽疗法的创新方案。</li>
<li>启动一项专门的新研究，评估 Adia Vita 在类风湿性关节炎（RA）患者中的应用，探索其在自身免疫和炎症性疾病中的潜在免疫调节和抗炎作用。</li>
</ul>
<p>“今年启动四到五项新研究标志着我们在通过严格、伦理的临床研究推进再生医学方面迈出了重要一步，” Adia Nutrition 首席执行官 Larry Powalisz 表示。“通过与全国领先的诊所合作，我们旨在加速 IRB 批准，扩大患者的获取渠道，并在神经发育、自身免疫和其他再生应用中生成高质量的数据。这些努力使 Adia Med 能够为患者护理和科学理解做出有意义的贡献。”</p>
<p>公司的旗舰人类试验——为期 24 个月的 ASD 研究，仍在全国和全球范围内积极招募 3-12 岁的儿童，继 2025 年底获得 BeyondBound IRB 批准后。与潜在合作诊所的讨论正在进行中，计划在未来几个月内提交 IRB 申请，以支持更广泛的 2026 研究议程。</p>
<p>Adia Vita 继续在再生和免疫支持的背景下提供医生指导的应用，所有研究均在严格的伦理监督、知情同意和法规合规下进行。</p>
<p><strong>如有问题、咨询或更多信息，请联系 Larry Powalisz，邮箱：ceo@adiamed.com，电话：321-788-0850。</strong></p>
<p>有意许可 Adia Med 名称或将 Adia 的再生疗法整合到其实践中的诊所所有者和医疗从业者，鼓励直接联系。欢迎战略合作伙伴关系，作为 Adia 继续扩大先进干细胞解决方案获取渠道的使命的一部分。</p>
<p><strong>关于 ADIA Nutrition Inc.：</strong></p>
<p>Adia Nutrition Inc.（OTCQB: ADIA）总部位于佛罗里达州温特帕克，是一家通过创新推动医疗保健的上市公司。该公司专注于通过其实验室部门 Adia Labs LLC 销售干细胞和再生产品，如 AdiaVita 和 AdiaLink，正在扩展以包括可报销的伤口护理产品。Adia 还在全国范围内发展，拥有专注于骨科、疼痛管理和伤口修复的 Adia Med 诊所。Adia Med 诊所还提供专门的再生治疗，如干细胞疗法和富血小板血浆（PRP），先进治疗包括治疗性血浆置换（TPE）和自体造血干细胞移植（aHSCT），以及伤口修复服务。</p>
<p>收入通过服务费用、产品销售、股权投资和医疗治疗的保险报销产生。此外，Adia Nutrition Inc.还投资于与其价值观相符的企业，如 Cement Factory LLC，一家专注于健康和保健的营养和补充品公司。通过与顶级医疗实体的大胆合作以及对标准化、FDA 批准实验室协议的坚定承诺，Adia Nutrition Inc.正在革新医疗保健，点燃全国范围内赋能社区的运动，提供突破性的再生解决方案和充满活力的整体健康。</p>
<p>网站：www.adianutrition.com</p>
<p>网站：www.adiamed.com</p>
<p>网站：www.adialabs.com</p>
<p>网站：www.cementfactory.co</p>
<p>Twitter (X)：@ADIA_Nutrition</p>
<p><strong>安全港声明：</strong> 本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明。这些前瞻性声明基于管理层当前的计划和期望，并受到一些不确定性和风险的影响，这可能会显著影响公司的当前计划和期望，以及未来的运营结果和财务状况。有关可能影响公司商业前景并导致实际结果与前瞻性声明中描述的结果有重大差异的风险和因素的更详细列表，可以在公司向证券交易委员会和 OTC 市场公司提交的报告和其他文件中找到。公司没有义务公开更新或修订任何前瞻性声明，因新信息、未来事件或其他原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/10520/282995_294b5aa6842cc9c7_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/10520/282995_294b5aa6842cc9c7_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/282995</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282995/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282995/375"/></p>

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

美国制药 ETF - iShares

<p>Adia Nutrition Inc. 计划在 2026 年启动四到五项新的临床研究，重点关注自闭症和类风湿关节炎的研究。该公司旨在扩展现有的自闭症谱系障碍研究，以包括年龄较大的儿童，并启动一项关于 Adia Vita 对类风湿关节炎患者影响的新研究。首席执行官 Larry Powalisz 强调了通过伦理临床研究和与全国各地诊所的合作推进再生医学的承诺。Adia Nutrition Inc. 继续在医疗保健领域进行创新，专注于干细胞和再生产品</p>

<p>Winter Park, Florida--(Newsfile Corp. - February 9, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its subsidiary Adia Med, today announced an ambitious expansion of its clinical research pipeline, with plans to launch four to five additional studies throughout 2026. These new initiatives will build on the company's ongoing success in regenerative therapies using Adia Vita (umbilical cord blood-derived stem cells and exosomes).</p>
<div class="lb-trans"><p>佛罗里达州温特帕克 --（Newsfile Corp. -2026 年 2 月 9 日）- Adia Nutrition Inc.（OTCQB: ADIA），通过其子公司 Adia Med 在再生医学领域处于领先地位，今天宣布了一项雄心勃勃的临床研究管道扩展计划，计划在 2026 年推出四到五项额外研究。这些新举措将建立在公司在使用 Adia Vita（脐带血来源的干细胞和外泌体）进行再生疗法方面的持续成功之上。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/10520/282995_autism_study_graphic_550.jpg" alt="" original-src="https://images.newsfilecorp.com/files/10520/282995_autism_study_graphic_550.jpg"/></p>
<p><strong>Autism Study Graphic</strong></p>
<div class="lb-trans"><p><strong>自闭症研究图示</strong></p>
</div><p>To view an enhanced version of this graphic, please visit:</p>
<div class="lb-trans"><p>要查看此图的增强版本，请访问：</p>
</div><p>https://images.newsfilecorp.com/files/10520/282995_autism_study_graphic.jpg</p>
<div class="lb-trans"><p>https://images.newsfilecorp.com/files/10520/282995_autism_study_graphic.jpg</p>
</div><p>The planned studies may be conducted directly at the Adia Med clinic in Winter Park, Florida, or in collaboration with partner clinics across the United States. To support this growth, Adia Med is actively in discussions with multiple clinics nationwide to secure Institutional Review Board (IRB) approvals and enable multi-site participation.</p>
<div class="lb-trans"><p>计划中的研究可能直接在佛罗里达州温特帕克的 Adia Med 诊所进行，或与美国各地的合作诊所合作进行。为了支持这一增长，Adia Med 正在与全国多家诊所积极讨论，以获得机构审查委员会（IRB）的批准，并实现多地点参与。</p>
</div><p>Among the priority efforts already under discussion are:</p>
<div class="lb-trans"><p>目前正在讨论的优先工作包括：</p>
</div><ul>
<li>An expansion of the current IRB-approved Autism Spectrum Disorder (ASD) study (ClinicalTrials.gov NCT07304440) to include 13-year-old children, extending eligibility beyond the existing 3-12 age range and allowing more families to access the innovative protocol combining Adia Vita with glutathione therapy.</li>
<li>The launch of a dedicated new study evaluating Adia Vita in patients with rheumatoid arthritis (RA), exploring its potential immune-modulating and anti-inflammatory effects in autoimmune and inflammatory conditions.</li>
</ul>
<div class="lb-trans"><ul>
<li>扩大当前获得 IRB 批准的自闭症谱系障碍（ASD）研究（ClinicalTrials.gov NCT07304440），将研究对象扩展到 13 岁的儿童，超出现有的 3-12 岁年龄范围，使更多家庭能够获得结合 Adia Vita 与谷胱甘肽疗法的创新方案。</li>
<li>启动一项专门的新研究，评估 Adia Vita 在类风湿性关节炎（RA）患者中的应用，探索其在自身免疫和炎症性疾病中的潜在免疫调节和抗炎作用。</li>
</ul>
</div><p>&#34;Launching four to five new studies this year marks a major step forward in our commitment to advancing regenerative medicine through rigorous, ethical clinical research,&#34; said Larry Powalisz, CEO of Adia Nutrition. &#34;By collaborating with leading clinics nationwide, we aim to accelerate IRB approvals, broaden patient access, and generate high-quality data across neurodevelopmental, autoimmune, and other regenerative applications. These efforts position Adia Med to make meaningful contributions to patient care and scientific understanding.&#34;</p>
<div class="lb-trans"><p>“今年启动四到五项新研究标志着我们在通过严格、伦理的临床研究推进再生医学方面迈出了重要一步，” Adia Nutrition 首席执行官 Larry Powalisz 表示。“通过与全国领先的诊所合作，我们旨在加速 IRB 批准，扩大患者的获取渠道，并在神经发育、自身免疫和其他再生应用中生成高质量的数据。这些努力使 Adia Med 能够为患者护理和科学理解做出有意义的贡献。”</p>
</div><p>The company's flagship human trial-the 24-month ASD study-remains actively recruiting children aged 3-12 nationwide and worldwide, following BeyondBound IRB approval in late 2025. Discussions with potential partner clinics are progressing, with targeted IRB submissions in the coming months to support the broader 2026 research agenda.</p>
<div class="lb-trans"><p>公司的旗舰人类试验——为期 24 个月的 ASD 研究，仍在全国和全球范围内积极招募 3-12 岁的儿童，继 2025 年底获得 BeyondBound IRB 批准后。与潜在合作诊所的讨论正在进行中，计划在未来几个月内提交 IRB 申请，以支持更广泛的 2026 研究议程。</p>
</div><p>Adia Vita continues to be available for physician-directed applications in regenerative and immune-supportive contexts, with all research conducted under strict ethical oversight, informed consent, and regulatory compliance.</p>
<div class="lb-trans"><p>Adia Vita 继续在再生和免疫支持的背景下提供医生指导的应用，所有研究均在严格的伦理监督、知情同意和法规合规下进行。</p>
</div><p><strong>For questions, inquiries, or additional information,</strong> please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.</p>
<div class="lb-trans"><p><strong>如有问题、咨询或更多信息，请联系 Larry Powalisz，邮箱：ceo@adiamed.com，电话：321-788-0850。</strong></p>
</div><p>Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.</p>
<div class="lb-trans"><p>有意许可 Adia Med 名称或将 Adia 的再生疗法整合到其实践中的诊所所有者和医疗从业者，鼓励直接联系。欢迎战略合作伙伴关系，作为 Adia 继续扩大先进干细胞解决方案获取渠道的使命的一部分。</p>
</div><p><strong>About ADIA Nutrition Inc.:</strong></p>
<div class="lb-trans"><p><strong>关于 ADIA Nutrition Inc.：</strong></p>
</div><p>Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.</p>
<div class="lb-trans"><p>Adia Nutrition Inc.（OTCQB: ADIA）总部位于佛罗里达州温特帕克，是一家通过创新推动医疗保健的上市公司。该公司专注于通过其实验室部门 Adia Labs LLC 销售干细胞和再生产品，如 AdiaVita 和 AdiaLink，正在扩展以包括可报销的伤口护理产品。Adia 还在全国范围内发展，拥有专注于骨科、疼痛管理和伤口修复的 Adia Med 诊所。Adia Med 诊所还提供专门的再生治疗，如干细胞疗法和富血小板血浆（PRP），先进治疗包括治疗性血浆置换（TPE）和自体造血干细胞移植（aHSCT），以及伤口修复服务。</p>
</div><p>Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.</p>
<div class="lb-trans"><p>收入通过服务费用、产品销售、股权投资和医疗治疗的保险报销产生。此外，Adia Nutrition Inc.还投资于与其价值观相符的企业，如 Cement Factory LLC，一家专注于健康和保健的营养和补充品公司。通过与顶级医疗实体的大胆合作以及对标准化、FDA 批准实验室协议的坚定承诺，Adia Nutrition Inc.正在革新医疗保健，点燃全国范围内赋能社区的运动，提供突破性的再生解决方案和充满活力的整体健康。</p>
</div><p>Website: www.adianutrition.com</p>
<div class="lb-trans"><p>网站：www.adianutrition.com</p>
</div><p>Website: www.adiamed.com</p>
<div class="lb-trans"><p>网站：www.adiamed.com</p>
</div><p>Website: www.adialabs.com</p>
<div class="lb-trans"><p>网站：www.adialabs.com</p>
</div><p>Website: www.cementfactory.co</p>
<div class="lb-trans"><p>网站：www.cementfactory.co</p>
</div><p>Twitter (X): @ADIA_Nutrition</p>
<div class="lb-trans"><p>Twitter (X)：@ADIA_Nutrition</p>
</div><p><strong>Safe Harbor:</strong> This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.</p>
<div class="lb-trans"><p><strong>安全港声明：</strong> 本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明。这些前瞻性声明基于管理层当前的计划和期望，并受到一些不确定性和风险的影响，这可能会显著影响公司的当前计划和期望，以及未来的运营结果和财务状况。有关可能影响公司商业前景并导致实际结果与前瞻性声明中描述的结果有重大差异的风险和因素的更详细列表，可以在公司向证券交易委员会和 OTC 市场公司提交的报告和其他文件中找到。公司没有义务公开更新或修订任何前瞻性声明，因新信息、未来事件或其他原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/10520/282995_294b5aa6842cc9c7_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/10520/282995_294b5aa6842cc9c7_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282995</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/282995</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282995/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/282995/375"/></p>

Adia Nutrition Inc. Plans to Initiate Four to Five New Clinical Studies in 2026, Including Expansions in Autism and New Rheumatoid Arthritis Research | ADIA Stock News

StockTitan

医疗业 ETF - Vanguard

Aadi Biosciences

Invesco Nasdaq Biotechnology ETF

2 倍做多纳斯达克生物技术 ETF - ProShares

标普全球医疗股指数 ETF - iShares

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - SPDR

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

Adia Nutrition Inc.计划在 2026 年启动四到五项新的临床研究，其中包括自闭症领域的扩展研究和新的类风湿性关节炎研究 | ADIA 股票新闻